Triamcinolone acetonide .25 mg/g Ointment
Other active recalls for Triamcinolone Acetonide (different manufacturers) — 1 · tap to view
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Corticosteroid class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Triamcinolone topical is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). It is also used as a dental paste to relieve the discomfort of mouth sores. Triamcinolone is in a class of medications called corticosteroids. It works by activating natural substances in the skin to reduce swelling, redness, and itching.
Read the full MedlinePlus article ↗- Yes, intra-articular triamcinolone is specifically approved to give short-term relief for knee arthritis, gout flares, bursitis, and similar joint conditions. The extended-release...
- I'm getting a triamcinolone injection in my knee. Will it actually help, and how long does it last?
- That's a really important thing to flag with your doctor before your injection or prescription. Triamcinolone can raise blood sugar — even in people whose diabetes is well-controll...
- I have diabetes. Should I be worried about using triamcinolone?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Triamcinolone Acetonide — tap one for details:
Triamcinolone Acetonide may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Where does this data come from?
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII T5L8T28FGP
Mineral oil is a clear, odorless liquid derived from crude oil. It acts as a lubricant and emollient in medications, helping pills slide smoothly during manufacturing and aiding moisture retention in topical products.
-
UNII 4T6H12BN9U
Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.
2 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.244 | $3.66 / 15 g |
| Medicaid paysCMS SDUD · 12 mo | $0.3653 | $5.48 / 15 g |
| Medicare drug plans payPart D · Q2 2026 | $0.3820 | $5.73 / 15 g |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Triamcinolone Acetonide .25 mg/g 45802-0063-05 | Padagis | 454 g | $0.036 | AT | Availability likely | save 85% |
| Triamcinolone Acetonide .25 mg/g 45802-0054-05 | Padagis | 454 g | $0.047 | AT | Availability likely | save 81% |
| Triamcinolone Acetonide .25 mg/g 00168-0005-80 | E. | 80 g | $0.076 | AT | Availability likely | save 69% |
| Triamcinolone Acetonide .25 mg/g 00713-0226-15 | Cosette | 1 tube | $0.116 | AT | Discontinued | save 52% |
| Triamcinolone Acetonide .25 mg/g 16714-0985-01 | NorthStar | 1 tube | $0.116 | AT | Availability likely | save 52% |
| Triamcinolone Acetonide .25 mg/g 33342-0327-15 | Macleods | 1 tube | $0.116 | AT | Availability likely | save 52% |
| Triamcinolone Acetonide .25 mg/g 67877-0317-15 | Ascend | 15 g | $0.116 | AT | Availability likely | save 52% |
| triamcinolone acetonide .25 mg/g 00168-0003-15 | E. | 1 tube | $0.116 | AT | Availability likely | save 52% |
| Triamcinolone Acetonide .25 mg/g 00713-0229-15 | Cosette | 1 tube | $0.244 | AT | Availability likely | — |
| Triamcinolone acetonide .25 mg/g 16714-0267-01 | NorthStar | 1 tube | $0.244 | AT | Availability likely | — |
| Triamcinolone acetonide .25 mg/gthis 33342-0331-15 | Macleods | 1 tube | $0.244 | AT | Availability likely | — |
| Triamcinolone Acetonide .25 mg/g 50090-3802-00 | A-S | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 63629-8841-01 | Bryant | 80 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 72162-2335-02 | Bryant | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 76420-0360-80 | Asclemed | 80 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 63187-0214-80 | Proficient | 80 g | — | AT | FDA listed | — |
| triamcinolone acetonide .25 mg/g 50090-0293-01 | A-S | 1 tube | — | AT | FDA listed | — |
| Triderm .25 mg/g 00316-0165-15 | Crown | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 76420-0347-15 | Asclemed | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 63629-8782-01 | Bryant | 15 g | — | AT | FDA listed | — |
| triamcinolone acetonide .25 mg/g 68788-8515-08 | Preferred | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 68788-8899-01 | Preferred | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 72162-2334-02 | Bryant | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 63629-8784-01 | Bryant | 454 g | — | AT | FDA listed | — |
| Triamcinolone acetonide .25 mg/g 68071-2361-01 | NuCare | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 50090-3704-00 | A-S | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 71335-2870-01 | Bryant | 454 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 50090-2658-00 | A-S | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 72162-1835-02 | Bryant | 454 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 68788-4148-01 | Preferred | 1 tube | — | AT | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
🗺️ Medicaid utilization & spend
💊 Medicaid utilization by pack size
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Status |
|---|---|---|---|---|---|
| 33342-0331-15 You're viewing this | 1 TUBE in 1 CARTON (33342-331-15) / 15 g in 1 TUBE | $0.2440 / g | $3.66 | 2018-11-23 | Active |
| 33342-0331-54 | 454 g in 1 JAR (33342-331-54) | $0.0472 / g | $21.43 | 2018-11-23 | Active |
| 33342-0331-80 | 1 TUBE in 1 CARTON (33342-331-80) / 80 g in 1 TUBE | $0.0763 / g | $6.10 | 2018-11-23 | Active |
Per g, this pack runs about 417% above the cheapest pack (454 g, $0.0472 vs $0.2440 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 52% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in NDC 33342-0331-15?
What NDC number is used to bill for this package of Triamcinolone acetonide .25 mg/g Ointment?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS & USAGE Triamcinolone Acetonide Ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
⏱️ Dosage and Administration ▾
DOSAGE & ADMINISTRATION Apply a thin film of Triamcinolone Acetonide Ointment 0.025% to the affected area two to four times daily. Apply a thin film of the 0.1% or the 0.5% Triamcinolone Acetonide Ointment, as appropriate, to the affected area two to three times daily. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions.
Apply a thin film of ointment to the lesion, cover with a pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis.
It may be convenient to apply Triamcinolone Acetonide Ointment under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional ointment should be applied, without occlusion, during the day. Reapplication is essential at each dressing change.
If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
⛔ Contraindications ▾
CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
🤰 Pregnancy ▾
Pregnancy: Teratogenic Effects Category C. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.
There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
🧒 Pediatric Use ▾
Pediatric Use Pediatric patients may demonstrate greater susceptibility to topical corticosteroid induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio. HPA axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.
Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.
🆘 Overdosage ▾
OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS, General ).
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.
There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin.
Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION ).
Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.
Some of the topical corticosteroids and their metabolites are also excreted into the bile.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Triamcinolone Acetonide Ointment USP, 0.025% is available as follows: 15 gram tubes NDC 33342-331-15 80 gram tubes NDC 33342-331-80 454 g jar NDC 33342-331-54 Triamcinolone Acetonide Ointment USP, 0.1% is available as follows: 15 gram tubes NDC 33342-333-15 80 gram tubes NDC 33342-333-80 454 g jar NDC 33342-333-54 Triamcinolone Acetonide Ointment USP, 0.5% is available as follows: 15 gram tubes NDC 33342-332-15 Storage Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].
Manufactured for: Macleods Pharma USA, Inc. Princeton, NJ 08540 Manufacturer: Macleods Pharmaceuticals Limited At Oxalis Labs Baddi, Himachal Pradesh, INDIA To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc.at 1-888-943-3210 or 1-855-926- 3384 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Revised: July 2023
📋 Description ▾
DESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. The steroids in this class include triamcinolone acetonide. Triamcinolone acetonide is designated chemically as 9-Fluoro-11β, 16α, 17, 21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone.
The structural formula is: Each gram of Triamcinolone Acetonide Ointment USP, 0.025%, 0.1% or 0.5% contains 0.25 mg, 1 mg or 5 mg triamcinolone acetonide, respectively, in an ointment base of light mineral oil and white petrolatum. str
💬 Information for Patients ▾
Information for the Patient Patients using topical corticosteroids should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for external use only.
Avoid contact with the eyes. 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician. 4.
Patients should report any signs of local adverse reactions especially under occlusive dressing. 5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.